The company reported third-quarter 2019 operating results and deepened its relationship with Gilead Sciences.
News & Analysis: Galapagos
Biotechs trade on the prospects of new advancements to identify and treat diseases. That's something the world needs in good times and bad.
GLPG earnings call for the period ending September 30, 2019.
Which stock wins in a matchup between these two successful biotechs?
The Belgian biopharma bagged $5.1 billion from its most important partner.
GLPG earnings call for the period ending June 30, 2019.
Here's what Gilead's getting with its $5.1 billion Galapagos collaboration.
Despite already massive gains this year, shares of these drugmakers could keep on climbing.
From failed takeover talks to a massive new partnership, see why these stocks were on the move on a quiet day for the broader markets.
Gilead Sciences decided to inject $5.1 billion into its R&D partner Galapagos NV over the weekend.